Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Emmy Dolman"'
Autor:
Camilla Calandrini, Frans Schutgens, Rurika Oka, Thanasis Margaritis, Tito Candelli, Luka Mathijsen, Carola Ammerlaan, Ravian L. van Ineveld, Sepide Derakhshan, Sanne de Haan, Emmy Dolman, Philip Lijnzaad, Lars Custers, Harry Begthel, Hindrik H. D. Kerstens, Lindy L. Visser, Maarten Rookmaaker, Marianne Verhaar, Godelieve A. M. Tytgat, Patrick Kemmeren, Ronald R. de Krijger, Reem Al-Saadi, Kathy Pritchard-Jones, Marcel Kool, Anne C. Rios, Marry M. van den Heuvel-Eibrink, Jan J. Molenaar, Ruben van Boxtel, Frank C. P. Holstege, Hans Clevers, Jarno Drost
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Pre-clinical cell culture models capturing the heterogeneity of childhood kidney tumours are limited. Here, the authors establish and characterise an organoid biobank of tumour and matched normal organoid cultures from over 50 children with different
Externí odkaz:
https://doaj.org/article/06e35408aaed4de9ae4266eeecb8d988
Autor:
Elisha Hayden, Laura Franshaw, Dannielle Upton, Jie Liu, Hieu Nguyen, Swapna Joshi, Maria Tsoli, Emmy Dolman, Benjamin Rayner, David Ziegler
Publikováno v:
Cancer Research. 83:1561-1561
Diffuse Midline Gliomas (DMGs) are devastating and incurable pediatric brain tumours. DMGs are characterised by epigenetic aberrations in the form of histone modifications, coupled with mitotic abnormalities, which together drive a stem-like transcri
Autor:
Dieter Deforce, Dries Rombaut, Karen Verboom, Jan J. Molenaar, Suzanne Vanhauwaert, Pieter Mestdagh, Johan van Nes, G Schleiermacher, Bieke Decaesteker, Johannes H. Schulte, Filip Van Nieuwerburgh, Franki Speleman, Christophe Van Neste, Rogier Versteeg, Jolien De Wyn, Carl Herrmann, Katleen De Preter, Geertrui Denecker, Moritz Gartlgruber, Kaat Durinck, Daniel Dreidax, Pauline Depuydt, Fanny De Vloed, Valentina Boeva, Wouter Van Loocke, Waleed M. Kholosy, Frank Westermann, Bianca Koopmans, Emmy Dolman, Anke H. W. Essing, Carolina de Carvalho Nunes, Siebe Loontiens, Anton G. Henssen
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-17 (2018)
Nature Communications
Nature communications, 9(1). Nature Publishing Group
NATURE COMMUNICATIONS
Nature Communications
Nature communications, 9(1). Nature Publishing Group
NATURE COMMUNICATIONS
Chromosome 17q gains are almost invariably present in high-risk neuroblastoma cases. Here, we perform an integrative epigenomics search for dosage-sensitive transcription factors on 17q marked by H3K27ac defined super-enhancers and identify TBX2 as t
Autor:
Steven Goossens, Aline Eggermont, J. Van Laere, C. Van Neste, E De Smet, Amber Louwagie, F. Devloed, Volodimir Olexiouk, M. Rishfi, Matthias Fischer, Laurentijn Tilleman, Sven Eyckerman, Emmy Dolman, Vanessa Vermeirssen, Pauline Depuydt, Lisa Depestel, B. De Wilde, Liselot Mus, Bieke Decaesteker, Franki Speleman, Kaat Durinck, Louis Delhaye, K. M. Keller, F. Van Nieuwerburgh, Julie Morscio, W Van Loocke, Christoph Bartenhagen, Dieter Deforce, Ellen Sanders, Jan J. Molenaar, Stephen S. Roberts, Siebe Loontiens, Carolina de Carvalho Nunes, P. Van Vlierberghe
SummaryNeuroblastoma is a pediatric tumor originating from the sympathetic nervous system responsible for 10-15 percent of all childhood cancer deaths. Half of all neuroblastoma patients present with high-risk disease at diagnosis. Despite intensive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8cd9df042da04ccb024f1a9986dadc59
https://doi.org/10.1101/2020.11.25.397323
https://doi.org/10.1101/2020.11.25.397323
Autor:
Bianca Koopmans, Thomas F. Eleveld, Lindy Vernooij, Rogier Versteeg, Emmy Dolman, Huib N. Caron, Marli E. Ebus, Jan Koster, Lindy K. Alles, Peter van Sluis, Linda Schild, Jan J. Molenaar
Mutations affecting the RAS-MAPK pathway occur frequently in relapsed neuroblastoma tumors and are associated with response to MEK inhibition in vitro. However, these inhibitors alone do not lead to tumor regression in vivo, indicating the need for c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a149c61ba3deceda7fd2cabb881ad8a7
https://doi.org/10.1101/2020.02.12.945089
https://doi.org/10.1101/2020.02.12.945089
Autor:
Daniel Bexell, Suzanne Vanhauwaert, Tom Van Maerken, Shana Claeys, Johannes H. Schulte, Frank Westermann, Katleen De Preter, Bram De Wilde, Liselot Mus, Rogier Versteeg, Bieke Decaesteker, Caroline Wigerup, Genevieve Laureys, Jan J. Molenaar, Geertrui Denecker, Jean-Baptiste Demoulin, Christophe Van Neste, Sven Påhlman, Candy Kumps, Kristina Althoff, Kai Oliver Henrich, Kaat Durinck, Olivier De Wever, Ellen M. Westerhout, Emmy Dolman, Lea Wehrmann, Siebe Loontiens, Frank Speleman
Publikováno v:
Oncogene, 38(15), 2690-2705. Nature Publishing Group
Oncogene, Vol. 38, no.15, p. 2690-2705 (2019)
Oncogene, Vol. 38, no.15, p. 2690-2705 (2019)
ALK mutations occur in 10% of primary neuroblastomas and represent a major target for precision treatment. In combination with MYCN amplification, ALK mutations infer an ultra-high-risk phenotype resulting in very poor patient prognosis. To open up o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::090bb9075c39877c95a9950ea73e3318
https://pure.amc.nl/en/publications/alk-positively-regulates-mycn-activity-through-repression-of-hbp1-expression(ca3ddead-0d50-4c2d-b5a1-714060809bc5).html
https://pure.amc.nl/en/publications/alk-positively-regulates-mycn-activity-through-repression-of-hbp1-expression(ca3ddead-0d50-4c2d-b5a1-714060809bc5).html
Autor:
Marlinde L. van den Boogaard, Emmy Dolman, Nil A. Schubert, Jan J. Molenaar, Lindy K. Alles, Stijn van Oirschot, Lindy Vernooij, Marloes E. Nulle, Linda Schild, Kaylee M. Keller
Publikováno v:
Cancer Research. 80:A49-A49
Neuroblastomas account for approximately 15% of all childhood cancer deaths. Clinical complete remission is achieved in many stage 4 neuroblastoma patients, but the high risk of relapse and the accompanying treatment-resistant nature of these tumors
Publikováno v:
Cancer Research. 80:A40-A40
Background/Objectives: The most promising option to improve outcomes for pediatric cancer patients with relapsed or refractory disease is through mutation-based targeted therapeutic strategies. However, only 50% of these tumors harbor actionable even
Autor:
R.R. de Krijger, Sepideh Derakhshan, Camilla Calandrini, Lieve Tytgat, M.M. van den Heuvel-Eibrink, Jarno Drost, Jan J. Molenaar, Emmy Dolman
Publikováno v:
Annals of Oncology. 31:S18